Open an account

Acrivon Therapeutics

ACRV · NASDAQ

$1.80+$0.105 (+6.21%)TodayMarket closed ·
Prev close $1.69

About ACRV

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. The company is headquartered in Watertown, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2022-11-15. The company uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. The company is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.

Employees
74
Headquarters
Watertown, Massachusetts
Listed
Nov 15, 2022
Sector
Health Care
Industry
Biotechnology
Website
acrivon.com

ACRV key statistics

Market cap
76.92M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
272.88K
Volume
185.42K
Open price
$1.78
High today
$1.82
Low today
$1.75
52 Week high
$3.56
52 Week low
$1.27

Acrivon Therapeutics (ACRV) at a glance

As of Oct 20, 2026, Acrivon Therapeutics (ACRV) shares are priced at $1.80, giving the company a market cap of 76.92M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.75 and $1.82. The current price is 2.6% above the day's low and 1.4% below its high.

Volume so far is 185.42K shares, below the average of 272.88K shares a day.

Over the past year Acrivon Therapeutics has ranged from $1.27 to $3.56, and now sits 23% of the way up that range.

Acrivon Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.43 per share against an estimate of -$0.51.

The average analyst price target is $12.44, 593.3% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $12.44
Low
$7.07
Now
$1.80
High
$19.95

ACRV earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 14.7% on average.

  1. Q3 FY24: reported -$0.59 per share against an estimate of -$0.5893
  2. Q4 FY24: reported -$0.60 per share against an estimate of -$0.6811
  3. Q1 FY25: reported -$0.51 per share against an estimate of -$0.6551
  4. Q2 FY25: reported -$0.55 per share against an estimate of -$0.598
  5. Q3 FY25: reported -$0.47 per share against an estimate of -$0.6018
  6. Q4 FY25: reported -$0.52 per share against an estimate of -$0.4756
  7. Q1 FY26: reported -$0.49 per share against an estimate of -$0.5359
  8. Q2 FY26: reported -$0.43 per share against an estimate of -$0.51

ACRV news

  • Press releaseGlobe Newswire

    Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

  • Press releaseGlobe Newswire

    Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit

  • Press releaseGlobe Newswire

    Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

  • Press releaseGlobe Newswire

    Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress

  • Press releaseGlobe Newswire

    Registration Momentum Builds Across the Oncology Pipeline

  • Press releasePRNewswire

    Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment

  • Avi Kapoor

    Dow Jumps Over 250 Points; US Initial Jobless Claims Increase

  • Avi Kapoor

    Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings

Similar companies

Companies in the same industry as Acrivon Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.